Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Equillium, Inc. (EQ : NSDQ)
 
 • Company Description   
Equillium, Inc. is a biotechnology company. It develops products for autoimmune and inflammatory disorders. The company's product pipeline consists of EQ001 which is in clinical-stage. Equillium, Inc. is based in CA, United States.

Number of Employees: 45

 
 • Price / Volume Information   
Yesterday's Closing Price: $2.50 Daily Weekly Monthly
20 Day Moving Average: 25,257 shares
Shares Outstanding: 34.28 (millions)
Market Capitalization: $85.69 (millions)
Beta: 1.31
52 Week High: $7.75
52 Week Low: $2.12
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -15.25% -7.21%
12 Week -37.19% -29.41%
Year To Date -33.69% -18.99%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
2223 Avenida de la Playa Suite 105
-
LA JOLLA,CA 92037
USA
ph: 858-412-5302
fax: -
ir@equilliumbio.com http://www.equilliumbio.com
 
 • General Corporate Information   
Officers
Bruce D. Steel - President and Chief Executive Officer
Daniel M. Bradbury - Chairman of the Board of Directors
Jason A. Keyes - Chief Financial Officer
Stephen Connelly - Director
Martha J. Demski - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 29446K106
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/09/22
Share - Related Items
Shares Outstanding: 34.28
Most Recent Split Date: (:1)
Beta: 1.31
Market Capitalization: $85.69 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.38 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.39 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/09/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.63
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -36.36%
vs. Previous Quarter: -25.00%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -63.54
12/31/21 - -48.97
09/30/21 - -46.35
ROA
03/31/22 - -50.49
12/31/21 - -40.62
09/30/21 - -38.85
Current Ratio
03/31/22 - 5.50
12/31/21 - 9.35
09/30/21 - 11.85
Quick Ratio
03/31/22 - 5.50
12/31/21 - 9.35
09/30/21 - 11.85
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 1.54
12/31/21 - 2.26
09/30/21 - 2.58
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.14
12/31/21 - 0.13
09/30/21 - 0.12
Debt-to-Capital
03/31/22 - 12.28
12/31/21 - 11.63
09/30/21 - 10.48
 

Powered by Zacks Investment Research ©